Haq Syed H, Pulver Riley, Begmatov Hoshimjon, Downing Candace, Laird Amanda, Patel Sandeep M, Chanamolu Sreenivasa, Cole William
Department of Internal Medicine, BonSecours Mercy Health-St.Rita's Medical Center, Lima, OH.
Department of Critical Care Medicine, BonSecours Mercy Health-St. Rita's Medical Center, Lima, OH.
Crit Care Explor. 2025 Aug 6;7(8):e1301. doi: 10.1097/CCE.0000000000001301. eCollection 2025 Aug 1.
Intrapulmonary hemorrhage (IPH) is a life-threatening condition associated with specific risk factors including prolonged mechanical ventilation, therapeutic anticoagulation, and notably, mechanical circulatory support (MCS). MCS creates a constellation of conditions that predispose patients to IPH. Given the need for systemic anticoagulation and concomitant critical illness, managing IPH can be challenging. Consequently, extracorporeal membrane oxygenation (ECMO) is accompanied by an increased mortality rate.
We present a case of a patient on ECMO complicated by severe intrapulmonary bleeding refractory to conventional therapies, but responded to the novel application of Surgiflo (a hemostatic matrix) to achieve hemostasis.
Endobronchial application of Surgiflo provides a viable option to manage refractory IPH.
肺内出血（IPH）是一种危及生命的病症，与特定风险因素相关，包括长时间机械通气、治疗性抗凝，尤其是机械循环支持（MCS）。MCS会引发一系列使患者易患IPH的情况。鉴于需要全身抗凝以及伴随的危重病，管理IPH可能具有挑战性。因此，体外膜肺氧合（ECMO）伴随着死亡率的增加。
我们报告一例接受ECMO治疗的患者，该患者并发严重肺内出血，对传统疗法无效，但对新型止血材料Surgiflo的应用有反应，从而实现了止血。
支气管内应用Surgiflo为管理难治性IPH提供了一种可行的选择。
